Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
The disclosure provides methods of treating a condition of the retina by administering an inhibitor of connexin 36 and/or an inhibitor of connexin 45 to a subject with a retinal condition. This disclosure further provides compositions for the treatment of a retinal condition which include an inhibitor of connexin 36 and/or an inhibitor of connexin 45.
1. A method of treating glaucoma by blocking gap junctions comprising administering a therapeutically effective amount of a non-selective inhibitor of connexin 36 to a subject in need thereof, wherein said non-selective inhibitor is 18-Beta-glycyrrhetinic acid (18Beta-GA), and wherein the therapeutically effective amount is at a concentration of 25 μM.
2. The method of claim 1 , comprising repeat administration of said inhibitor for a period of 1 week to 1 year.
3. The method of claim 1 , wherein said administration is topical administration or intraocular injection.